|
|
|
|
|
We’ve extended the clinical eligibility criteria for nusinersen for spinal muscular atrophy (SMA). Type III SMA patients who are not able to walk are now eligible for this treatment. This follows a review of data collected as part of a managed access agreement between NHS England and NHS Improvement, and Biogen.
|
|
The draft guideline recommends that looked-after children and young people are surrounded by a care network consisting of positive relationships. Supporting continuity of relationships with social workers, considering programmes to support mentoring relationships, and providing funding to enable contact with friends are also recommended. This guideline aims to help address the health inequalities often experienced by looked after children.
|
|
|
Around 70,000 adults in England with primary hypercholesterolaemia or mixed dyslipidaemia, also known as high cholesterol, will now be eligible for treatment with bempedoic acid with ezetimibe. Our new guidance recommends this as a treatment option for people who are unable to use statins and whose high cholesterol is not well-controlled with ezetimibe alone.
|
|
This guideline addresses several areas where new evidence has become available since we published our previous guideline in 2014. These include the use of tools to calculate the risk of bleeding when considering the use of anti-clotting drugs (anticoagulants); the role of newer anti-clotting drugs; and the use of treatments that aim to destroy or isolate abnormal sources of electrical impulses in the heart that may be driving AF.
|
|
|
In a recent Q&A for the Evidence Hub, Páll Jónsson, NICE’s associate director for science, policy and research, explains how NICE plans to make greater use of real-world evidence and shares his views on its continued impact on health technology assessment.
|
|
|
Bronchiolitis: when less is more
During the winter months, bronchiolitis was having a big impact on acute paediatric services across the South Eastern Health and Social Care Trust. The trust found that more babies were being admitted and staying longer in hospital.
To address this, the team implemented recommendations from our guideline on bronchiolitis in children to:
- Determine better admission criteria and what red flag advice to give to parents. This allowed more babies to be cared for at home.
- Put together 7 PDSA (plan, do, study, act) cycles for staff which promoted the guideline around the clinical areas.
By applying the recommendations:
- the percentage of babies admitted to the inpatient ward decreased from 43.8% to 32%
- 43 fewer babies were admitted in winter 2018/19, leading to a financial saving of over £70,000
- unnecessary interventions decreased, creating further financial savings.
This project is one of many implementation case studies contained in our shared learning collection.
|
|
|
Impact report on diagnostic pathology published
The report explores how NICE’s evidence-based guidance contributes to improvements in diagnostic pathology, as well as highlighting where progress still needs to be made.
|
|
Implementing our workplace health guidance
David Stacey is a public health programme manager at Lincolnshire County Council. He’s also a former NICE scholar. During his scholarship, David reviewed 37 HR policies in the council's employment manual, incorporating recommendations from 3 of our workplace health guidelines.
NICE scholarships are 1-year opportunities to find out about the inner workings of NICE. Scholars undertake a supported improvement project, related to our guidance, within a local organisation, national charity or voluntary sector organisation.
|
|
Comment on a consultation
Our current consultations include:
|
|
Consultation is a key part of our guidance development process. It enables those with an interest in our guidance to comment at specific stages and feedback into the decision-making process.
|
|
Join a committee
We have 1 vacancy for lay people to join our committees. Join and have an active role in producing a guideline or quality standard.
|
|
Observe a meeting
Due to the pandemic, we're holding all our public meetings virtually. You'll need to register in advance to join.
Upcoming public meeting:
- Wednesday 8 and Thursday 9 June 2021 – Public health advisory committee C meeting
- Social, emotional and mental health wellbeing
Registration closes Wednesday 2 June 2021.
Agenda and register
- Tuesday 15 June 2021 – Diagnostics advisory committee meeting
- Assessment of SeHCAT (tauroselcholic acid) for the investigation of bile acid diarrhoea
Registration closes Tuesday 8 June 2021.
Agenda and register
- Wednesday 16 June 2021 – Quality standards advisory committee 3 meeting
- Brain tumours (primary) and brain metastases in adults
Registration closes Wednesday 9 June 2021.
Agenda and register
|
|
|
Our advisory committee meetings, technology appraisal appeal hearings and public board meetings are open to the public. Holding them in public supports our commitment to having processes in place that are rigorous, open, and transparent.
|
|
|
Zanele Mndebele, senior business analyst at NICE explains how new functionality for online collaboration on our guideline consultations, enables groups or organisations to submit a joined-up response.
|
|
Mark Salmon, programme director for information resources at NICE, reveals 2 exciting developments which will accelerate our efforts to deliver innovation to the health and care system.
|
|
|
Join us for HTAi 2021 virtual annual meeting
We will be co-hosting the Health Technology Assessment international’s (HTAi) annual meeting on:
- Saturday 19 to Wednesday 23 June 2021.
This year, the main theme of the meeting is ‘Innovation through health technology assessment (HTA)’. NICE is taking part in various sessions including panels on ‘the importance of regulatory science in HTA’ and ‘keeping patients at the heart of NICE guidance development’.
Details on the speakers, plenary sessions, workshops and presentations can be found on the HTAi 2021 virtual annual meeting website.
|
|
|
We’ve published an updated memorandum of understanding agreement with the Care Quality Commission (CQC). The agreement describes how both organisations will work together, in a coordinated way, to inform and accelerate improvements in the quality and safety of care.
|
|
NICE joins forces with partners to found the GetReal Institute
The GetReal Institute’s core mission is to facilitate the adoption and implementation of real-world evidence in healthcare decision-making across Europe. This aligns with our ambition set out in our 5-year strategy, to play a leadership role in data, research and science.
NICE will join 9 other organisations pending finalisation and execution of the membership agreement:
- Clinical Practice Research Datalink
- Eli Lilly and Company
- Hoffmann-La Roche
- GlaxoSmithKline
- International Alliance of Patients’ Organizations
- Janssen, Pharmaceutical Companies of Johnson & Johnson
- Norwegian Medicines Agency
- University Medical Center Utrecht.
|
|
|
|
|
|
|
